Events
We are very much looking forward to the 2022 edition of the Neuro4D conference, which will take place in Mainz, Germany, on May 16 and 17. Priavoid GmbH will be represented by two speakers. Antje Willuweit will give a talk titled “Development of therapeutic substances for the disassembly of α-synuclein aggregates” at around 5 p.m. on Monday, April 16. Dieter Willbold will be speaking about our Alzheimer’s program PRI-002 on May 17 at around 1:30 p.m. His presentation is titled “PRI-002: towards clinical phase II – preclinical proof of concept and clinical phase I data”
We are looking forward to seeing many more exciting presentations and, of course, to seeing you!
About Priavoid GmbH:
Priavoid GmbH is a spin-off of Research Center Jülich and Heinrich Heine University Düsseldorf. The company was founded in 2017 and is based in Düsseldorf. It develops novel all-d-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. The most advanced of these is PRI-002 for Alzheimer’s disease. All drug candidates are designed to have an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. The company is privately funded, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner. In addition, the development is significantly supported by the German Federal Agency for Disruptive Innovations, which is funding the PRIMUS-AD phase II study for the drug candidate PRI-002.